Screener / SEC EDGAR /CIK 0001579428 /10-K filed Feb 23, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Axsome Therapeutics, Inc. AXSM

Compare with peers Embed
SEC comment letters, last 20 years

1 review of AXSM's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Sep 22, 2015
Questions asked 20 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 1 UPLOAD
  2. 2. Questions in them 20 numbered comments
  3. 3. Company replies 1 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2015-09-22 to 2015-10-13 · 20 questions · 1 letter from the SEC, 1 from the company
No closing letter
Risk factorsCritical estimates
Prospectus Summary · Overview, page 1
SEC asked (1)
Please describe the meaning and significance of the following terms the first time you use them in this section:  Osteoclast inhibitor;  Zoledronic acid; and  Bone resorption markers.
AXSM answered
In response to the Staff’s comment, the Company has revised the following disclosures on page 1 of the Revised Registration Statement to now state:

“Our first product candidate, AXS-02 (disodium zoledronate tetrahydrate), is a potentially first-in-class, oral, targeted, non-opioid therapeutic for chronic pain.
Rest of the answer

AXS-02 is a potent inhibitor of osteoclasts, which are bone remodeling cells that break down bone tissue.”

“In this trial, oral administration of AXS-02 tablets resulted in rapid absorption of zoledronic acid, which is the active molecule in AXS-02 and the free acid form of disodium zoledronate tetrahydrate, and substantial suppression of bone resorption markers, which are proteins indicative of bone tissue breakdown.”

Read in the reply
Our Pipeline, page 3
SEC asked (2)
On page 5, you state that you plan to request a meeting with the FDA in 2016 to discuss your development plans for AXS-05 for the treatment of agitation in patients with AD. Your table should clearly indicate which phases of clinical trials have been completed. As your discussion states that you have completed phase 1 clinical trials, please revise your pipeline table to remove the gray portion of the arrow.
AXSM answered
In response to the Staff’s comment, the Company has revised the pipeline table throughout the Revised Registration Statement to reflect the change requested above.
Read in the reply
AXS-02, page 3
SEC asked (3)
At your first reference to the 505(b)(2) regulatory development pathway, please expand your disclosure to describe this process and its significance to your development of AXS02 and AXS-05. Similarly, please provide the meaning and significance of FDA Fast Track designation the first time you refer to it on page 3.
AXSM answered
In response to the Staff’s comment, the Company has added the following disclosure to pages 1 and 3 of the Revised Registration Statement, respectively:

“Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FDCA, enables a potentially shorter development timeline for our product candidates by allowing us to rely, in part, upon published literature or the FDA’s previous findings of safety and efficacy for an approved product with the active molecules in our product candidates and potentially forego conducting certain clinical trials and certain lengthy and costly preclinical
Rest of the answer

studies.”

“The FDA’s Fast Track program is designed to expedite the development and review of drugs that are intended to treat serious or life-threatening conditions by providing greater access to, and more frequent communication with, the FDA throughout the drug development process.”

Read in the reply
Risk Factors, page 13
SEC asked (4)
Under an appropriately titled risk factor, please discuss Dr. Tabuteau’s conflicts of interest as your CEO and owner of Antecip. The discussions should address conflicts relating to the license agreements; his roles as your CEO and Chairman of the Board and managing member of Antecip; and the allocation of his time between these roles.
AXSM answered
In response to the Staff’s comment, the Company has inserted the following risk factor on page 17 of the Revised Registration Statement:

“Potential conflicts of interest exist with respect to the intellectual property rights that we license from an entity owned by our Chief Executive Officer and Chairman of the Board, and it is possible that our interests and their interests may diverge.

In 2012, we entered into three exclusive license agreements with Antecip Bioventures II LLC, or Antecip, an entity owned by our Chief Executive Officer and Chairman of the Board, Herriot Tabuteau, M.D., in
Rest of the answer

which we were granted exclusive licenses to develop, manufacture, and commercialize Antecip’s patents and applications related to the development of our current product candidates. See “Business—Material License Agreements.” Although Dr. Tabuteau dedicates all of his working time to us because Antecip is an inactive intellectual property holding company, he may face potential conflicts of interest regarding these licensing transactions as a result of his ownership of Antecip. The license agreements provide that, subject to the reasonable consent of Antecip, we have the right to control the prosecution or defense, as the case may require, of a patent infringement claim involving the licensed intellectual property. Our interests with respect to pleadings and settlements in such cases may be at odds with those of Antecip. If there is a dispute between us and Antecip, Dr. Tabuteau will have a conflict of interest because he may, at the time of a prospective dispute, simultaneously have a financial interest in and owe a fiduciary duty to Antecip and simultaneously have a financial interest in and owe a fiduciary duty to us. For example, if a contractual dispute arises between us and Antecip under any of the license agreements we have with Antecip, Dr. Tabuteau may be in a position where he would benefit if Antecip prevails, to the detriment of our business or our investors, even though he is an officer and director of our company, because he is the sole owner of Antecip. Similarly, if we have a claim of any kind against Antecip, Dr. Tabuteau may be, even as our Chief Executive Officer and Chairman of the Board, reluctant to assert a claim by us against Antecip because of his financial interest in Antecip. We cannot assure you that any conflicts will be resolved in our favor, and as a result, our business could be impeded or materially harmed.”

Read in the reply
Risks Related to Intellectual Property · Obtaining and maintaining our patent protection depends on compliance with…, page 47
SEC asked (5)
The title of this risk factor references compliance with various procedural, documentary, fee payment, and other requirements imposed by governmental patent agencies in order to obtain and maintain your patent protection; however, your risk factor disclosure does not discuss any of these requirements and the risks associated with them.
Rest of the question

Please revise your risk factor disclosure to discuss the referenced requirements, which government agencies have imposed them and the risk of non-compliance with the requirements.

AXSM answered
In response to the Staff’s comment, the Company has revised the body of this risk factor on page 49 of the Revised Registration Statement to now state:

“The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent prosecution process.
Rest of the answer

Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents or patent applications will be due to be paid to the USPTO and various patent agencies outside of the United States in several stages over the lifetime of the patents and applications. We have systems in place to remind us to pay these fees, and we employ and rely on reputable law firms and other professionals to effect payment of these fees to the USPTO and non-U.S. patent agencies for the patents and patent applications we own and those that we in-license. We also employ reputable law firms and other professionals to help us comply with the various documentary and other procedural requirements with respect to the patents and patent applications that we own and those that we in-license. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.”

Read in the reply
We may be involved in lawsuits to protect or enforce our patents or the patents…, page 49
SEC asked (6)
Please expand your risk factor disclosure to describe whether you or Anticep is responsible for enforcement of the patents you license from Anticep.
AXSM answered
In response to the Staff’s comment, the Company has revised the body of this risk factor on page 50 of the Revised Registration Statement:

“Competitors may infringe our issued patents, our in-licensed patents, or other intellectual property that we own or in-license. Under the terms of our license agreements with Antecip, if we believe a third party is infringing on the patents subject to the licenses, we are obligated, at our own expense, to initiate suit against those third parties.
Rest of the answer

To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part; construe the patent’s claims narrowly; or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Most of our competitors are larger than we are and have substantially greater resources than we do. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in-license needed technology, or enter into development partnerships that would help us bring our product candidates to market.”

Read in the reply
Use of Proceeds, page 66
SEC asked (7)
Please revise your disclosure in the first two bullet points to describe how far in the development process of AXS-02 and AXS-05 you estimate the allocated proceeds from this offering will enable you to reach for each of the listed indications.
AXSM answered
In response to the Staff’s comment, the Company has revised the bullet points on page 68 of the Revised Registration Statement to now state:

· “approximately $19 to $25 million to fund our clinical trials for AXS-02, including the completion of our ongoing Phase 3 trial in pain associated with CRPS and our planned Phase 3 trial in the pain of knee OA associated with BMLs, and the launch of our planned Phase 3 trial in CLBP associated with MCs;

· approximately $14 to $17 million to fund our ongoing development of AXS-05, including the launch and completion of our planned Phase 3 trial of
Rest of the answer

AXS-05 in TRD; and

· the remainder for further development of our product candidates, working capital, and general corporate purposes.”

Read in the reply
Critical Accounting Policies and Significant Judgments and Estimates · Stock-Based Compensation and Fair Market Value of Stock, page 73
SEC asked (8)
We may have additional comments on your accounting for equity issuances including stock based compensation. Once you have an estimated offering price, please provide us an analysis explaining the reasons for the differences between the recent valuations of your common stock leading up to the IPO and the estimated offering price.
AXSM answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the Company will provide the Staff with this analysis at such time as an estimated offering price has been determined.
Read in the reply
Business · Overview, page 86
SEC asked (9)
Please identify the one product that is approved in the United States for the treatment of TRD.
AXSM answered
In response to the Staff’s comment, the Company has revised the following sentence on page 89 of the Revised Registration Statement to now state:

“Currently only one product, Symbyax, a combination of olanzapine and fluoxetine, which is marketed by Eli Lilly and Company, is approved in the United States for the treatment of TRD.”
Read in the reply
AXS-02, page 89
SEC asked (10)
Under the appropriate subsection for AXS-02, please disclose when an investigational new drug application (“IND”) was filed for the commencement of clinical trials for the product candidate, the name of the trial sponsor and the subject of the IND.
AXSM answered
In response to the Staff’s comment, the Company has added the following disclosure to page 98 of the Revised Registration Statement:

“We submitted an Investigational New Drug Application, or IND, sponsored by us, in October 2013 for AXS-02 for the treatment of pain associated with CRPS.”
Read in the reply
Rationale for the Use of AXS-02 in CPRS · Effects of AXS-02 in the rat tibia fracture model of CRPS, page 92
SEC asked (11)
We note your disclosure in the first full paragraph on page 93 that oral administration of AXS-02 “significantly” reversed pain, improved weight bearing and prevented edema as compared to placebo in the rat tibia fracture model of CRPS and the related p-values shown in the accompanying figure.
Rest of the question

Please revise your disclosure to clarify that the improvement in pain, weight bearing and edema was statistically significant. In addition, please explain the relationship between “statistical significance” and “p-values” and the significance of p-values to the FDA’s evidentiary standards of efficacy.

AXSM answered
In response to the Staff’s comment, the Company has revised the first sentence of the first full paragraph on page 95 of the Revised Registration Statement to now state:

“Oral administration of AXS-02 resulted in a statistically significant reduction in pain, improvement in weight bearing, and prevention of edema as compared to placebo in the rat tibia fracture model of CRPS.”

In addition, the Company has added the following sentences to the end of that same paragraph:

“An experimental result, such as those derived from a clinical or non-clinical study, is statistically significant if it
Rest of the answer

is unlikely to have occurred by chance. The statistical significance of experimental results is determined by a widely used statistical method that establishes the P value of the results. A P value is a statistical measure of the probability that the difference in results between treatment and control groups in a study could have occurred by chance. Under this method, the smaller the P value the greater the confidence that the results are significant, and a P value of 0.05 or less is generally considered by the FDA to represent statistical significance.”

Read in the reply
Rationale for the Use of AXS-02 in CPRS · Effects of AXS-02 in the rat tibia fracture model of CRPS, page 92
SEC asked (12)
Please expand your disclosure regarding the second study using the same rat tibia model where the results of the study showed a “significant” reduction in pain and “improvement” in weight bearing to provide the results of the trial which led to this conclusion.
Rest of the question

If the reduction in pain was also “statistically significant” in this study, please revise your disclosure to use the term “statistically significant” rather than the term “significant.” Please also make similar revisions to your disclosure for the other clinical trials discussed in your prospectus to use the term “statistically significant” rather than “significant” where appropriate.

AXSM answered
In response to the Staff’s comment, the Company has revised the final paragraph on page 95 of the Revised Registration Statement to now state:

“We conducted a second study using the same rat tibia fracture model. In this study, the animals underwent tibia fracture and casting as described above, but dosing of AXS-02 was started following cast removal and continued for a duration of three weeks. Oral administration of AXS-02 resulted in a statistically significant reversal of pain and improvement in weight bearing as compared to placebo.
Rest of the answer

Treatment with AXS-02 reversed pain by approximately 100% versus baseline and improved weight bearing by approximately 13% as compared to placebo. The study did not find an effect of AXS-02 on edema or hindpaw temperature.”

Further, in response to the Staff’s comment, the Company has made several revisions throughout the Revised Registration Statement to use the term “statistically significant” where appropriate.

Read in the reply
AXS-05 · Overview, page 101
SEC asked (13)
Please revise your diagram on page 102 to define the acronym DXO.
AXSM answered
In response to the Staff’s comment, the Company has revised the diagram on page 104 of the Revised Registration Statement to define the acronym DXO. In addition, the Company has inserted the following additional disclosure on page 104 of the Revised Registration Statement:

“DM is active at multiple CNS receptors but is rapidly metabolized into dextrorphan, or DXO, when dosed alone.”
Read in the reply
Treatment Resistant Depression · Rationale for the Development of AXS-05 in Agitation in Patients with AD, page 105
SEC asked (14)
We note that a significantly greater reduction for active treatment as compared to placebo in the agitation/aggression domain of the NPI was seen in both stage 1 and stage 2 of the study discussed in this section. Please expand your disclosure to also provide the results of stage 2 of the study which support this conclusion.
AXSM answered
In response to the Staff’s comment, the Company has revised the second sentence in the second full paragraph on page 108 of the Revised Registration Statement to now state:

“A statistically significantly greater reduction in the agitation/aggression domain of the NPI for active treatment as compared to placebo was seen in both stage 1 as well as in stage 2 of the study.
Rest of the answer

During stage 1, a reduction of 3.3 in the agitation/aggression domain of the NPI was seen for active treatment as compared to a reduction of 1.7 for placebo, with a P value that is less than 0.001, as shown in the figure below. During stage 2, a reduction of 2.0 was observed for active treatment as compared to a reduction of 0.8 for placebo, with a P value that is equal to 0.02. Average baseline values for the agitation/aggression domain of the NPI were 7.1 for the active treatment group and 7.0 for the placebo group.”

Read in the reply
Preclinical Programs, page 108
SEC asked (15)
We note your disclosure on pages 17 and 108 that AXS-04 is a product candidate that is currently in early-stage development. If this product candidate is in preclinical development, please expand your disclosure in this section and throughout your prospectus as appropriate to describe AXS-04.
Rest of the question

Otherwise, please advise us supplementally if you have not yet identified an indication for this product candidate and have therefore concluded that it is premature to include it in your preclinical program discussion.

AXSM answered
In response to the Staff’s comment, the Company confirms that it has not yet identified an indication for AXS-04 and the Company has therefore concluded that it would be premature to include further information in the preclinical program discussion.
Read in the reply
Intellectual Property, page 109
SEC asked (16)
Please revise your disclosure for your patent portfolio for AXS-02 and AXS-05 to provide the following information:  whether the patents are owned or licensed from Anticep;  the expiration date of issued patents separate from the expected expiration dates if your patent applications are approved;  the foreign jurisdictions where your AXS-02 patents are issued and patent applications are pending; and  the
Rest of the question

jurisdictions where your AXS-05 patent is issued and patent applications are pending. Certain Relationships and Related Party Transactions Consulting Agreement with Mark Coleman, M.D.

AXSM answered
In response to the Staff’s comment, the Company has revised the first full paragraph on page 112 of the Revised Registration Statement to now state:

“Our intellectual property portfolio contains 13 issued patents and 3 allowed and more than 50 pending applications in the United States and worldwide. Twelve issued patents and more than 35 pending patent applications covering our AXS-02 product candidate have claims covering method of delivery, pharmacokinetics, composition of matter, and methods of use with protection extending through 2034 for both our issued patents and pending
Rest of the answer

applications. In addition to patent protections, our AXS-02 program, if approved, may also be afforded potential exclusivity by the FDA’s and EMA’s orphan drug designation programs for CRPS, which provide 7 years and 10 to 12 years of exclusivity, respectively. One issued patent and 3 allowed and several pending patent applications covering our AXS-05 product candidate have claims covering pharmaceutical composition, drug delivery, and pharmacokinetics with protection extending through 2032 to 2034 for our issued and allowed patents, as well as our pending applications. We have pending PCT applications, as well as pending applications in Australia, Canada, China, Europe, Hong Kong, Japan, South Korea, and New Zealand. We have other patent applications with claims covering the other programs in our pipeline, including those that are not relevant to our current programs in development. We have licensed the patents and pending applications which cover AXS-02, AXS-04, and AXS-05 from Antecip. All of the other components of our intellectual property portfolio are owned by Axsome.”

Certain Relationships and Related Party Transactions

Consulting Agreement with Mark Coleman, M.D.

Read in the reply
Intellectual Property, page 109
SEC asked (17)
Please file the consulting agreement with Mr. Coleman as an exhibit.
AXSM answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that Dr. Coleman’s consulting agreement with the Company has been filed as an exhibit with the attached Revised Registration Statement.
Read in the reply
Other Comments
SEC asked (18)
We note that there are a number of additional exhibits that still need to be filed. Please provide these exhibits as promptly as possible. Please note that we may have comments on these materials once they are provided.
AXSM answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that most of the exhibits not filed with the Initial Submission are being filed with the attached Revised Registration Statement. The Company will provide the remaining exhibits as promptly as possible.
Read in the reply
Other Comments
SEC asked (19)
Please confirm that the graphics included in your registration statement are the only graphics you will use in your prospectus. If those are not the only graphics, please provide any additional graphics prior to their use for our review.
AXSM answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that the images included in the Registration Statement are all of the graphic, visual or photographic information the Company currently intends to include in the Registration Statement. If the Company decides to use any additional images, it will provide the Staff with proofs of such materials as soon as practicable.
Read in the reply
Other Comments
SEC asked (20)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
Rest of the question

If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11, 2012 announcement on the SEC website at http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm. Please keep in mind that we may publicly post filing review correspondence in accordance with our December 1, 2011 policy (http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm). If you intend to use Rule 83 (17 CFR 200.83) to request confidential treatment of information in the correspondence you submit on EDGAR, please properly mark that information in each of your confidential submissions to us so we do not repeat or refer to that information in our comment letters to you.

AXSM answered
The Company acknowledges the Staff’s request and respectfully advises the Staff that, to date, no written communications, as defined in Rule 405 under the Securities Act, have been presented by the Company, or anyone authorized to act on the Company’s behalf, to potential investors. The Company intends to supplementally provide the Staff with copies of all such written communications presented to potential investors in reliance on Section 5(d) of the Securities Act as promptly as practicable following such presentation, if any.
Rest of the answer

The Company advises the Staff that potential investors will not be permitted to retain copies of such written communications. The Company further advises the Staff that to its knowledge, as of the date hereof, no research reports have been distributed by any broker or dealer participating in the offering.

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
5 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 7 letters filed since 2015-09-22. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AXSM/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.